Aerobic Exercise Increases Protein That May Suppress Appetite

In a small study of overweight and obese adults, 3 months of aerobic exercise, with no change in diet, led to a significant decrease in body fat and a spontaneous decrease in caloric intake. The percentage of weight loss and the reduction in caloric intake correlated positively and significantly with concentrations of brain-derived neurotrophic factor (BDNF). "The reduction in caloric intake could be related to the effect of BDNF in appetite regulation," Dr. Henry Anhalt of the Animas Corporation, West Chester, Pennsylvania told the Endocrine Society’s 90th annual meeting in San Francisco.
"It is possible that the increases in this compound in fact suppress appetite; however, this was not directly tested," added Dr. Anhalt, who moderated a press conference where the study was reported.

In the study, Dr. A. Veronica Araya and colleagues from University of Chile Clinical Hospital in Santiago evaluated blood levels of BDNF before and after 3 months of aerobic exercise in 15 overweight or obese men and women. The 7 men and 8 women, ages 26 to 51 years, exercised on a treadmill and bicycle.

At the end of the 3-month exercise period, study subjects experienced a significant decrease in BMI (from 30.6 to 30.1; p = 0.01), waist circumference (from 108.1 to 105.1 cm; p = 0.003) and percentage body fat (35.2 to 33.3%; p = 0.0029).
They also experienced a fall in systolic blood pressure (128.7 to 122.6 mmHg; p = 0.05) and diastolic blood pressure (82.3 to 72.6 mmHg; (p = 0.007), and spontaneously consumed fewer calories each day (2142 to 1805 cal; p = 0.01).

Serum BDNF rose from 2.4 ng/mL before exercise to 7.8 ng/mL after exercise (p = 0.001), and "the concentration of BDNF was correlated positively with the percentage of weight loss to a fairly high degree," Dr. Anhalt reported for Dr. Araya, who was unable to attend the press conference where the findings were released.

In a statement issued through the Endocrine Society, Dr. Araya said: "It is important to clarify the factors involved in the response to different weight loss therapies, because we could find a marker to predict response to the intervention."
Endocrine Society’s 90th annual meeting in San Francisco.

===============================

FACT:

Novo Nordisk Gets FDA Approval for PrandiMet: Novo Nordisk announced the FDA approval for PrandiMet, the first and only fixed-dose combination of the fast-acting insulin secretagogue repaglinide and metformin for the treatment of type-2 diabetes.  According to Novo Nordisk, PrandiMet has been approved as an adjunct to diet and exercise in adult patients with type-2 diabetes whose hyperglycemia cannot be controlled satisfactorily by meglitinide and/or metformin.  PrandiMet combines two antihyperglycemic agents with different mechanisms of action in one tablet to improve glycemic control and is available in two dosage strengths, dosed 2-3 times per day with meals. PrandiMet two dosage strengths include 1mg repaglinide/500mg metformin and 2mg repaglinide/500mg metformin. It is expected to be available to physicians and patients in the U.S. in the second half of 2008.

===============================

Advertisement
A1cNow New 20 Pack
A1CNow+ provides consistent, lab accurate results without the use of expensive capital equipment. As low as $9.50 per test
https://www.a1ctest.com/